Oncology
Conference Coverage
Oral SERD camizestrant prolongs PFS vs. fulvestrant in breast cancer
The investigational selective estrogen receptor degrader showed efficacy in advanced ER+/HER2– breast cancers, including patients with ESR1...
Conference Coverage
Chemotherapy meets its match against aggressive ER+/HER2– breast cancers
Ribociclib plus endocrine therapy resulted in high response rates and double progression-free survival over combo chemotherapy.
Conference Coverage
Potential cause of worse outcomes among Black breast cancer patients found
Tumor microenvironment of metastasis doorways predicted worse outcomes in Black women with residual ER+/HER2– cancer after neoadjuvant...
Latest News
Subset of patients with melanoma have very low mortality risk
The authors were interested in identifying lesions that are currently diagnosed as melanoma but might lack the capacity for metastasis.
From the Journals
‘Game changer’: Thyroid cancer recurrence no higher with lobectomy
Patients with intermediate-risk papillary thyroid cancer who undergo lobectomy versus total thyroidectomy as the surgical approach show no...
Feature
Less than a third of Americans aware of cancer risk from alcohol
Survey also shows low awareness that cancer risk varies by type of drink.
From the Journals
Not all plant-based diets equal for CRC risk reduction
Findings of a new study suggest that the benefits from plant-based diets may vary by sex, race, and ethnicity.
Latest News
Pandemic caused treatment delay for half of patients with CTCL, study finds
No clinical trials exist to inform maintenance protocols in patients with cutaneous lymphomas.
From the Journals
Doctor urges compassionate access to specialized radiotherapy for inoperable RCC
SABR should be considered for patients with larger, inoperable kidney cancers who have no treatment options.
From the Journals
Over half of targetable NSCLC patients miss out on correct tx
For some patients it could mean missing the chance for long-term survival or even cure.
News
FDA requests more restrictions on ovarian cancer drugs
Several companies have already withdrawn their respective PARP inhibitors for heavily pretreated patients with ovarian cancer.